Persistent challenges with treating multiple myeloma early

Abstract Over the past decade, 2 strategies have advanced treatment of patients with multiple myeloma and its precursor diseases. First, definition has changed to include without end organ damage, who previously would not been treated. Second, there is widespread enthusiasm for treating high-risk, smoldering myeloma. In this commentary, we explore evidence supporting these therapeutic expansions. Although early adds cost burden, it remains unknown whether survival health-related quality life are improved by treatment. Herein, consider implications diagnostic expansion in